Cassaday & Co Wealth Management’s Immunovant IMVT Stock Holding History

Cassaday & Co Wealth Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$224	Buy	+9	New	+$233	﹤0.01%	1257

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cassaday & Co Wealth Management's IMVT Position: Q1 2026 in Review

Cassaday & Co Wealth Management opened a new position in Immunovant (IMVT) in Q1 2026: 9 shares worth $224. The stake represents ﹤0.01% of the portfolio and ranks #1257 among its holdings.

215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Cassaday & Co Wealth Management held 9 shares of Immunovant worth $224 as of Q1 2026.
Immunovant was a new Cassaday & Co Wealth Management position in Q1 2026.
Immunovant made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q1 2026, its #1257 holding.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.